自江西施美药业股份有限公司（简称"施美药业"）递交招股书以来，其上市进程颇受外界关注。深交所 官网近日显示，施美药业回复了首轮问询，重点针对公司业务及行业情况、业绩变动趋势、毛利率等方 面问题进行了回复。 《经济参考报》记者注意到，尽管施美药业在招股书中自称"专注于仿制药、改良型创新药、创新药的 研发、生产及销售"，但其收入均来自于仿制药领域，改良型创新药、创新药尚处于研发阶段，在监管 问询下，施美药业调整了相关表述；此外，施美药业毛利率不仅远超同业平均水平，且其医药研发与定 制化生产业务毛利率还远超药明康德等CRO（受托研发）龙头公司，这也引发了监管的问询。 收入均来自于仿制药领域 施美药业成立于2002年11月，是一家以研发为核心驱动力的创新型医药企业，专注于仿制药、改良型创 新药、创新药的研发、生产及销售，并向客户提供自主研发技术成果转化、受托研发、定制化生产和委 托加工（CDMO）等一站式综合服务，核心业务主要包括医药研发与定制化生产业务和化学药制剂生产 销售业务。 本次冲刺创业板，施美药业计划募资6.08亿元，分别投入手性降压药物研发及产业化建设项目、山东创 新药物研发、制剂生产基地建设项目及山东科 ...

Core Viewpoint - The company is transforming its development momentum through the "Three New and Two Transformations" strategy, focusing on digital transformation, new retail, and new medical services to become the most professional health service provider in China and achieve its goal of becoming a century-old enterprise [1][7]. Digital Empowerment - The company has evolved from a grassroots pharmaceutical wholesaler to a technology-driven comprehensive service provider in the pharmaceutical industry, with a clear strategic path and implementation results in its digital transformation [1][2]. - The digital transformation includes collaboration across business, management, and logistics, with a focus on reducing costs and increasing efficiency [2][3]. - The company has achieved a significant reduction in logistics errors, with an error rate controlled at one in a million, enhancing both efficiency and quality [2]. Strategic Focus - The "Three New" strategy addresses the long-standing "two disconnections" in the industry by enhancing control over upstream products and establishing a new retail network for downstream channels [2][5]. - The company aims for new product-related sales to account for 20% of total revenue and 50% of gross profit in the next three years [3][5]. Medical Aesthetics Business - The company is accelerating its layout in the medical aesthetics sector, which has shown rapid growth, increasing from several million to several billion in scale [5][6]. - The medical aesthetics market is seen as a key profit growth point, driven by the aging population and rising consumer demand for beauty services [5][6]. Talent Strategy - The company has shifted its talent acquisition strategy, significantly increasing the recruitment of external senior talent to meet the demands of its strategic transformation [6][7]. - In 2023, the company introduced a "Three Transformations Talent Strategy," aiming to recruit over 300 senior talents annually [6]. Financial Performance - The company's sales revenue has grown from 21.185 billion in 2010 to 151.81 billion in 2024, with a compound annual growth rate of 15.10% [6]. - The net profit attributable to the parent company increased from 360 million in 2010 to 2.507 billion in 2024, with a compound annual growth rate of 14.88% [6].